5th Annual Translational Microbiome Conference – Boston, United States – April 16th-18th, 2019

Dublin, Feb. 13, 2019 (GLOBE NEWSWIRE) — The “5th Annual Translational Microbiome Conference – Industry” conference has been added to ResearchAndMarkets.com’s offering.

As the official conference of The Microbiome Coalition (TMBC), the Translational Microbiome Conference was the first microbiome conference in the field to focus exclusively on the hurdles and challenges to commercial success in the space.

Once again, the conference will bring together the leading microbiome companies working to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products across a range of therapeutic areas, from gut to skin and beyond. Expanding on this core focus year on year, we continue to offer informative, hands-on workshops, panels sponsored and directed by industry to focus on your concerns and tightly curated content that goes beyond the usual infomercials to provide tangible and useful insights to how your peers are addressing their commercial approach to the space.

Entering its 5th year in 2019, the meeting will continue to focus and build on the challenges and hurdles that companies working in the microbiome space will have to recognize and navigate in order to successfully commercialize their products.However, we are responding to requests by attendees to include more basic research, ensure more work beyond the gut is incorporated into the agenda and expanding our prior parallel tracks on nutrition and consumer products.


With a broad focus spanning multiple disease states (oncology, dermatology, inflammatory disorders, among others) attendees will have the opportunity to hear the leading companies discuss the work they have underway and how they are meeting these challenges head-on to apply recent discoveries to a variety of disease processes, restoration of health and improved outcomes.

Subject matter will include:

  • Animal Models
  • Bioinformatics Challenges
  • Intellectual Property Management
  • Investment Deals and Approaches
  • Pharma Deals in the Microbiome Space
  • The Need for Standards

Why Attend?

Partnering Software & Meetings
Easily schedule meetings with our partnering system in order to maximize your time at the event. Schedule one-to-one meetings in advance and stay connected after the event.

Industry-Leading Speaking Faculty
Our tightly curated content provides tangible and useful insights to how your peers are addressing their scientific, clinical and commercial approach to the space.

Network With Industry Colleagues
One-to-One meeting space, breakfasts, extended breaks, luncheons and receptions provide attendees with multiple opportunities to connect with colleagues in the space.

20+ Exhibitors/Service Providers
Meet with and/or re-connect with exhibitors and service providers and learn about the latest tools and resources driving the field of microbiome science.

Who Should Attend:

Academic Institutions, Bioscience Companies, Pharma Companies, Diagnostics Companies and Investors

Job Titles:

  • VPs, Directors, Heads, Scientists, Professors in following areas:
  • Microbiome/Microbiota basic research
  • NGS (Next Generation Sequencing)
  • Molecular Diagnostics
  • Autoimmune Disease Therapeutics
  • Infectious Diseases
  • Metabolic disease, Obesity, Diabetes
  • Genotyping
  • Genomics
  • Genomic Profiling
  • Biomarkers
  • Immunology Innate or Adaptive Immunity
  • Bioinformatics
  • Data Management
  • Data Analysis
  • Molecular Biology
  • Diagnostic & Clinical Applications
  • Prenantal Diagnostics
  • Vaccines
  • Microbiology
  • Food/Nutrition Science
  • Gut-Brain Axis Researchers
  • Venture Capitalists
  • Biotech Entrepreneurs
  • Academic Licensing or Tech Transfer Officers
  • Business Development/In-Licensing
  • FDA regulation
  • Clinical trials
  • Epigenetics
  • Metagenomics
  • High-Throughput Technologies
  • Data Analysis
  • Data Storage
  • Cloud Computing
  • Statistical Genomics



APRIL 16, 2019

2:30 pm Workshop I
Microbiome NGS and Hands-on Bioinformatic Data Analysis with Strain Level Resolution

Workshop Leaders: Nur Hasan, Ph.D., Chief Scientific Officer, Cosmos ID; Arne Materna, Ph.D., VP Product, Cosmos ID

3:15 pm Workshop II

Patenting in the Microbiome Arena

Workshop Leader: Mark Fitzgerald, Ph.D., Partner, Nixon Peabody LLP

5:30 pm Workshop III
What Investors Want, What Investors Notice and Value in a Pitch – The Secrets to Successful Venture Pitching

Workshop Leader: Lakshmi Balanchandra, Ph.D., Assistant Professor, Entrepreneurship, Blank Center for Entrepreneurship, Babson College, Founder, Women’s Venture Capital Network


APRIL 17, 2019

7:15 am Registration/Continental Breakfast

7:45 am Chairperson’s Opening Remarks
Mollie Roth, JD, Executive Director, The Microbiome Coalition

8:00 am Keynote Address: Microbial life at Scale: Applications, Analytics and Lessons Learned From the Food Supply Chain

Kristen L. Beck, Ph.D., Research Staff Member, Sequencing the Food Supply Chain, Almaden Research Center, IBM


8:30 am Biological, Chemical and Spatial Drivers of Microbiota Structure and Function: Therapeutic Implications

Elliot Friedman, Ph.D., Senior Research Investigator, Division of Gastroenterology, Technical Director, Microbial Culture & Metabolomics Core, PennCHOP Microbiome Program, Perelman School of Medicine, University of Pennsylvania

9:00 am Rapid Product Development: From Concept to Consumer Product
This talk will discuss BioCollective’s Approach to Rapid Probiotic/Prebiotic Prototyping using BioFlux Metabolic Modeling, existing extensive library of GRAS organisms/supply chain relationships, and small batch GMP production partners. Some of the most difficult challenges in formula development are:
US Regulatory – GRAS status vs. new organisms (many organisms have similar functions – modeling can identify alternatives to deliver identical function with an already approved organism)
Production – small batch photo-type product development, many vendors are already at maximum capacity and won’t do small production runs for prototyping-types
Production – moving from small batch to scaled production
Optimization – Organisms work as guilds, understanding the most synergistic combination can be simplified through metabolic modeling that closely mimics wet lab experiments
Martha Carlin, Chief Executive Officer, The BioCollective

9:30 am The Skin is NOT the Gut: Optimizing DNA Extractions and Amplicon Sequencing for the Skin Microbiome

Kelly N. Haas, Ph.D., Post Doctoral Scholar, Dermatology Department, University of California Davis

10:00 am Networking/Refreshment Break

10:30 am A Targeted, Point of Care Solution for Microbiome Analysis

Alicia Scheffer-Wong, Ph.D., Founder & CEO, Floragraph

11:00 am Lessons Learned: Translating Metagenomics into Clinical Routine

Nur Hasan, Ph.D., Chief Scientific Officer, Cosmos ID

11:30 am Panel Session: Enhancing the Power of the Microbiome Through Partnership

Moderator: Edward Burd, Ph.D., Head of Regulatory Affairs, Rebiotix
Lars Enstrand, MD, Ph.D., Director, Center for Translational Microbiome Research, Karolinska Institutet
Malcolm Kendall, CEO and Co-Founder, Microbiome Insights
Lindy Bancke, Pharm.D., Head of Clinical Development, Rebiotix
Greg Fluet, Chief Business Officer, Rebiotix


8:30 am Bringing Probiotic Products from Bench to Market in the U.S.

Duffy MacKay, ND, Senior VP, Scientific & Regulatory Affairs, Council for Responsible Nutrition

9:00 am Supporting Infant Development by Supporting the Developing Microbiota

Arthur Ouwehand, Ph.D., Technical Fellow and Research Manager, DuPont Nutrition & Health

9:30 am Perspectives on Future Success for Probiotics

Mary Ellen Sanders, Ph.D., Principal, Dairy and Food Culture Technologies

10:00 am Networking/Refreshment Break

10:30 am Panel Session: Probiotics: Aligning Science and Government Regulatory Requirements on a Path to Market
In this panel session, the following topics will be covered:

  • What traits to look for when selecting strains for probiotic applications – how to select beneficial strains
  • FDA regulatory path (GRAS) for probiotics
  • How to progress product candidates from in vitro and in vivo testing into clinical investigation
  • Interpretation of the clinical microbiome/probiotic data

Moderator: Maciej Chichlowski, Ph.D., PMP, Principal Scientist, Reckitt Benckiser
Duffy MacKay, ND, SVP, Scientific & Regulatory Affairs, Council for Responsible Nutrition
Arthur Ouwehand, Ph.D., Technical Fellow & Research Manager, DuPont Nutrition & Health
Mary Ellen Sanders, Ph.D., Principal, Dairy and Food Culture Technologies

11:15 am Use of the Probiotic Lactobacillus GG in Managing Food Allergies in Infants

Jon A. Vanderhoof, Attending Physician, GI/Nutrition, Boston Children’s Hospital, Senior Lecturer in Pediatrics, Harvard Medical School, Professor Emeritus of Pediatrics, University of Nebraska College of Medicine

11:45 am The First 1000 Days: Babies, Nutrition & Gut Health

Elisabeth Bik, Ph.D., Director of Science, Astarte Medical

12:15 pm Luncheon

1:15 pm Of Microbes and Monoamines: Stepping Stones from Dysbiosis to Psychiatric Disease

Stephen Skolnick, Translational Gerontology Branch, National Institutes on Aging, National Institutes of Health

1:45 pm Type 1 Diabetes: Primary Prevention Therapeutic Programs and First Pre-Autoantibody Biomarker Based on Association Between Autoimmunity and Dynamics of Amyloid-Producing E. Coli

George Tetz, MD, Ph.D., Chief Executive Officer, Human Microbiology Institute

2:15 pm The Human Microbiome: Towards Future Diagnostic and Clinical Solutions

Madhu Jasti, Scientist III R&D, Thermo Fisher Scientific

2:45 pm Strategies for Approaching FDA for Your First Clinical Trial

Nicole Rempel, MS, MBA, Director of Regulatory & Strategic Development, Clinipace
3:15 pm Networking/Poster-Viewing/Refreshment Break

3:45 pm Developing Products to Unlock the Promise of the Microbiome in Health and Disease: A Novel Approach, Challenges and Common Opportunities

Alison Lawton, Chief Executive Officer, Kaleido Biosciences

4:15 pm Panel Session: Confronting False Truths: On the Way to an IND, Is It Best to Avoid the FDA or Engage Early and Often?

Moderator: Nikole Kimes, Ph.D., Founder and Chief Scientific Officer, Siolta Therapeutics
Lee Jones, Founder, President and CEO, Rebiotix
Susan Stewart, JD, Senior Vice President, Regulatory Affairs & Quality, Kaleido Biosciences
Nicole Rempel, MS, MBA, Director, Regulatory and Strategic Development, Clinipace

5:00 pm The Asian Gut Microbiome: A New Therapeutics Discovery Opportunity

They have strategic partnerships with Hong Kong University and the Genome Institute of Singapore. In this presentation Jonathan will discuss the following:

  • How is the Asian gut microbiome different than the Western gut microbiome
  • How does fecal microbiota transplant yield new drug discovery opportunities
  • How the Asian gut microbes work in global population

Jonathan Krive, Co-Founder, CEO, AsiaBiome

5:30 pm Cocktail Reception

APRIL 18, 2019

7:30 am Continental Breakfast

8:00 am Keynote Address: Understanding the Role of the Microbiome in Cancer Immunotherapy

Jennifer Wargo, MD, Associate Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center

8:30 am Immuno-Oncology and the Microbiome

9:00 am Immuno-Oncology and the Microbiome

9:30 am Networking/Refreshment Break

10:00 am Panel Session: Immuno-Oncology and the Microbiome

10:45 am New Modeling Tools to Predict Dynamics of Microbial Ecologies
Vanni Bucci, Ph.D., Assistant Professor, University of Massachusetts Dartmouth
Bernat Olle, Ph.D., Chief Executive Officer, Vedanta Biosciences

11:15 am Statistical and Computational Tools for Functional Microbiome

Hongzhe Li, Ph.D., Professor of Biostatistics and Statistics, Chair, Graduate Program in Biostatistics, Director, Center for Statistics in Big Data, University of Pennsylvania

11:45 am From Conceptualization to Launch: A Case Study of a GI Microbiome Modulator

12:15 pm Luncheon

1:15 pm A Survivor’s Perspective: The Bigger Picture of the Patient Journey

1:45 pm Beyond Bacteria: Harnessing the Virome to Improve Our Understanding of Human Health and Inform Diagnostic and Therapeutic Applications

2:15 pm Microbial Signatures of Gut Wellness Through Multi-Study Integratlon of Human Stool Metagenomes

2:45 pm Networking/Poster-Viewing/Refreshment Break

3:15 pm Panel Session to be Announced

4:00 pm The First 1000 Days: Babies, Nutrition and Gut Health

4:30 pm End of Conference

Please check back in the coming days for additions to this agenda.

For more information about this conference visit https://www.researchandmarkets.com/research/qm7xwq/5th_annual?w=12

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Biopharmaceuticals